Background: We reviewed the effect of ovarian transposition (OT) on ovarian function among long-term survivors of childhood Hodgkin lymphoma (HL) treated with pelvic radiotherapy.
INTRODUCTION
Premature ovarian insufficiency (POI) is defined by the absence or interruption of spontaneous pubertal development in children and adolescents or by the onset of menopause before age 40 as a result of primary gonadal failure. 1 Up to 11% of female survivors of childhood cancer experience POI. [2] [3] [4] Lower ovarian reserve in young adulthood has been observed in women treated with chemotherapy and radiation therapy during childhood for Hodgkin lymphoma (HL). 5, 6 Exposure to high dose alkylating agents, quantified by cyclophosphamide equivalent dose (CED) ≥ 8,000 mg/m 2 , has been associated with POI, further highlighting the ovarian toxicity of these agents. 2 Pelvic radiotherapy can also cause irreversible ovarian damage and lead to infertility and other long-term health concerns such as decreased bone mineral density and frail health. 2 The estimated dose of radiation at which half of the follicles are lost in humans is 4-6 Gy in adults and 10-20 Gy in children. [7] [8] [9] Older age at radiotherapy has been associated with a higher risk of POI, likely because of the natural decline of ovarian reserve with age. 3 Ovarian transposition (OT) was proposed in 1958 as a means to preserve fertility in girls with tumors requiring pelvic irradiation. 10 This procedure involves relocation of the ovaries out of the irradiation field to minimize exposure of the ovaries to radiation, thereby preserving ovarian function. 11 Studies reporting on ovarian function in childhood cancer survivors who underwent OT have generally been limited and confined to those with small sample size and short follow-up.
The aim of this study was to evaluate the risk of POI and describe patterns of pregnancy and live births in a cohort of long-term female survivors of HL exposed to pelvic radiotherapy, including a subset who underwent OT before radiation.
MATERIAL AND METHODS

Study participants
Eligibility criteria for inclusion included the following: (1) females treated with pelvic radiotherapy during childhood for HL at St. Jude Children's Research Hospital (SJCRH); (2) survival of >10 years from diagnosis; and (3) attained age ≥ 18 years at follow-up. 12, 13 Eligible survivors underwent a clinical assessment on campus and completed a series of questionnaires pertaining to reproductive health prior to June 30, 2015. Survivors with a history of surgical menopause or bilateral oophorectomy before age 40 years, or hypothalamic or pituitary area irradiation were excluded. The study was approved by the institutional review board and the participants provided written informed consent prior to assessment.
Study outcomes
POI was defined as absence of menses 5 years post cancer diagnosis or loss of spontaneous menses prior to 40 years of age with laboratory or historic evidence of primary (ovarian) origin. The diagnosis of POI was based on the medical history provided by the patients in regards to puberty, menarche, menstrual cycles, pregnancies, childbirth, use of hormonal therapies including contraception, and timing of menopause, and supplemented by clinical and laboratory data from the St. Jude Lifetime Cohort Study (SJLIFE) evaluation. 2 In the absence of treatment with oral contraceptive pills or sex-hormone replacement therapy (HRT) at the time of SJLIFE participation, individuals <40 years old experiencing amenorrhea for a period > 6 months and having plasma estradiol levels < 17 pg/ml coinciding with follicle stimulating hormone levels ≥ 30 IU/l were considered to have POI. The diagnosis of POI was based on historical medical information only in participants treated with oral contraceptives or HRT. 2 Additional information on pregnancy and live births was obtained from questionnaires.
Study variables
Exposure to alkylating agents was quantified using the validated CED. 14 
Statistical analyses
Descriptive statistics were used to characterize participants and nonparticipants, as well as those who underwent OT and those who did not. Characteristics were compared between groups with Fisher exact test or Wilcoxon rank sum test, as appropriate. Cox proportional hazard regression was used to examine associations between treatments (OT, CED, and pelvic radiation) and POI after adjusting for age at diagnosis. Time-to-event analysis was used to compare pregnancies and live birth deliveries between survivors with and without OT, with POI considered a competing risk. Analyses were completed in SAS version 9.4 (Cary, NC) and R 3.4.2.
RESULTS
Characteristics of study participants
Of 127 eligible females with HL, 90 (80%) participated in SJLIFE, including 49 who underwent OT before pelvic radiotherapy ( Figure 1 ).
Participants did not differ from nonparticipants by race/ethnicity, age at diagnosis of HL, age at OT, pelvic radiation dose, CED, nitrogen mustard dose, or procarbazine dose (Table 1) . However, participants who underwent OT were younger when diagnosed with HL (P = 0.04) and received significantly higher doses of pelvic radiation (P < 0.0001) and more alkylating agents (P = 0.04) compared to survivors who did not undergo OT (Table 2 ). Among survivors who underwent an OT, an open surgical technique was used in 48 (98%) and a laparoscopic approach in one (2%). Bilateral midline OT was performed in all cases.
Risk factors associated with POI
In multivariable models, there was no significant association between OT and occurrence of POI (hazard ratio [HR] = 0.6, 95% confidence interval [CI] = 0.2-1.9; P = 0.41). However, pelvic radiotherapy doses > 1,500 cGy (HR = 25.2, 95% CI = 3.1-207.3; P = 0.0027) and exposure to alkylating agents at cumulative CED > 12,000 mg/m 2 (HR = 11.2, 95% CI = 3.4-36.8; P < 0.0001) were associated with an increased risk of POI (Table 3) . A multivariable subanalysis was F I G U R E 1 Consort diagram conducted to examine associations between OT, pelvic radiation dose, and POI among survivors who received lower CED (< 12,000 mg/m 2 ).
After adjusting for age at diagnosis, there was a significant association between POI and pelvic radiation dose (HR = 17.8, 95% CI = 2.3-136.5; P = 0.0057) but not with OT (HR = 1.1, 95% CI = 0.5-2.7; P = 0.8052) ( Table 4 ).
Ovarian function between survivors who did or did not undergo OT
The median age at POI for survivor participants with or without OT was not significantly different (22.7 Table 2 ). Among the 49 survivors who had OT, 30 (61%) reported at least one pregnancy, and for those who reported pregnancy, 27 (90%) reported a live birth delivery at least once. The probability of a first pregnancy or a live birth before age 40 did not differ between OT and non-OT groups (P = 0.1360 and P = 0.4970, respectively) ( Figure 2 ).
DISCUSSION
Our study provides long-term follow-up data on the effect of OT on ovarian outcomes (POI, pregnancy, and live births) in a cohort of clinically assessed HL survivors treated with pelvic radiotherapy. The study is unique in its ability to assess the effect of OT in relation to gonadotoxic therapy that may impact ovarian function, and in the extended duration of follow-up, which is among the longest reported to date. This study is timely, given the increased availability of modern fertility preservation techniques, and the need for data to assist childhood cancer survivors and their families to make the best decisions possible in regard to future fertility and family planning. 15 Prior studies have reported variable success rates of OT performed at staging laparotomy for female patients with HL in regard to the preservation of ovarian function, ranging from 0% to 66%. [16] [17] [18] [19] [20] [21] In this study, OT did not appear to modify the long-term risk of POI among female survivors of HL. However, it is important to note that OT was performed in a higher proportion of individuals treated with the highest doses of pelvic irradiation and exposure to higher doses of alkylating agents, which could have been a source of substantial bias. In addition, the effects of gonadotoxic treatments may have overwhelmed potential long-term gains from OT. Notably, age at first pregnancy and pregnancy/live birth history were not significantly different between patients with or without OT, despite the fact that survivors with OT were treated with higher doses of pelvic irradiation.
Our study indicates that OT may not prevent ovarian injury with the use of combined modality therapy, including pelvic radiotherapy doses > 1,500 cGy and alkylating agents exceeding a CED > 12,000 mg/m 2 . Prior studies with smaller numbers of patients, and shorter follow-up, have observed variable results in regard to the preservation of ovarian function following OT and pelvic irradiation.
Pregnancies have been reported in women who have had OT, but small cohort sizes precluded the inclusion of patient and treatment factors that may confound or modify the association between OT and preserved ovarian function. Ray et al. 17 reported preservation of ovarian function in 59% of 22 patients who underwent OT, one of whom gave birth to a normal baby girl. Le Floch et al. 18 reported on nine patients least one pregnancy, with no significant difference between OT (61%) and non-OT (76%) groups. In a meta-analysis of 1,189 premenopausal women with cancer requiring primary or postoperative radiotherapy (median age of 32 years), ovarian function following OT was preserved in 70% of women. 21 However, patients were only followed for a median of 4 years (range, 2-16) and the study only included women exposed to pelvic radiation. The median age at OT in our study was 15 years (range, 4-24) and the median age at evaluation was 38 years (range, 25-60). Our findings highlight the importance of long-term follow-up to better define the role of OT in delaying the onset of menopause in cancer survivors. Therefore, the findings do not allow the quantification of the radiation dose reduction brought about by the procedure, which is subject F I G U R E 2 Cumulative incidence plot for the probability of first pregnancy (A) and live birth over time (B) to variations depending on the individual's anatomy and the success of the procedure itself. Fourth, data pertaining to pregnancy and live birth history depended on the accurate completion of relevant questionnaires. Self-report data are always subject to recall bias, although maternal recall of reproductive history is generally accurate. 23 Fifth, the observed results in survivors who underwent OT may be a result of an operative failure or procedural complication that was not recorded.
TA B L E 1 Comparison of presenting features and treatments between study participants and nonparticipants
Participants
This study does not address potentially pre-existing conditions of the ovary, and that may have already affected the follicular reserve, such as unilateral oophorectomy. Further discussion of operative complications is warranted. Finally, the cross-sectional design of this study poses specific challenges in reporting the outcomes of interest given that a subset of patients may still go on to experience either POI or pregnancies with further follow-up.
In summary, OT did not appear to modify the long-term risk of POI and the pregnancy/live birth events in this historic cohort of long-term survivors of HL treated with combined pelvic radiation and alkylating agents. Modern fertility preservation modalities, such as mature oocyte cryopreservation, should be offered to at-risk patients whenever feasible.
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